By Iain Gilbert
Date: Tuesday 27 Jan 2026
(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
| European Commission approves Arexvy for adults 18+ | 26-Jan-2026 | 07:00 | RNS |
| GSK to acquire RAPT Therapeutics | 20-Jan-2026 | 07:05 | RNS |
| Agreement on changes to ViiV minority shareholding | 20-Jan-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 16-Jan-2026 | 15:30 | RNS |
| Director/PDMR Shareholding | 15-Jan-2026 | 15:30 | RNS |
| GSK to buy US food allergy specialist for $2.2bn | 20-Jan-2026 | Times |
| GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
| Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
| GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
| Ebola vaccine trials 'encouraging', says GSK | 27-Nov-2014 | Telegraph |
| Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
| Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
| Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
| Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
| Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 1,876.50p |
| Change Today | 24.50p |
| % Change | 1.32 % |
| 52 Week High | 1,901.50p |
| 52 Week Low | 1,264.00p |
| Volume | 8,804,792 |
| Shares Issued | 4,075.43m |
| Market Cap | £76,475m |
| Beta | 1.03 |
| RiskGrade | 129 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 4 |
| Buy | 3 |
| Neutral | 13 |
| Sell | 3 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| Q3 | Q2 | |
| Ex-Div | 13-Nov-25 | 14-Aug-25 |
| Paid | 08-Jan-26 | 09-Oct-25 |
| Amount | 16.00p | 16.00p |
| Time | Volume / Share Price |
| 16:18 | 0 @ 1,868.00p |
| 16:28 | 2 @ 1,868.50p |
| 16:03 | 1 @ 1,866.50p |
| 16:03 | 1 @ 1,866.50p |
| 15:47 | 1 @ 1,868.00p |
You are here: research